Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
- Resource Type
- journal article
- Authors
- Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar; Rau, Joern; Mahner, Sven; Pautier, Patricia; El-Balat, Ahmed; Kurtz, Jean-Emmanuel; Canzler, Ulrich; Sehouli, Jalid; Heubner, Martin L.; Hartkopf, Andreas D.; Baumann, Klaus; Hasenburg, Annette; Hanker, Lars C.; Belau, Antje; Schmalfeldt, Barbara; Denschlag, Dominik; Park-Simon, Tjoung-Won; Selle, Frédéric
- Source
- Journal of Clinical Oncology; 2/1/2023, Vol. 41 Issue 4, p893-902, 10p
- Subject
- Language
- ISSN
- 0732183X